Towards the prevention of cardiac failure in the chronic phase
Researchers at Osaka University have developed a therapeutic method using periostin1-specific neutralizing antibodies to inhibit the onset of cardiac failure in the chronic phase, improving patients' quality of life and reducing medical costs. The study's findings suggest that periostin1 is the primary cause of cardiac failure after AMI.